Начало・Списък с акции・Repligen Corp

Repligen Corp

Затворен

СекторЗдравеопазване

159.38 1.21

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

154.16

Максимум

162.13

Ключови измерители
By Trading Economics
Приходи	-3.3M 5M
Продажби	9.9M 204M
P/E Средно за сектора	201.452 68.51
EPS	0.54
Марж на печалбата	2.453
Служители	2,000
EBITDA	-35M -2.4M

Препоръки
By TipRanks
Препоръки	Силна покупка
12-месечна прогноза	+8.74% upside

Дивиденти
By Acuity
Следващи печалби	27.10.2026 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	907M 8.3B
Предишно отваряне	158.17
Предишно затваряне	159.38

Настроения в новините

By Acuity

20%

80%

46 / 340 Класиране в Healthcare

Repligen Corp Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

5.08.2026 г., 20:02 ч. UTC

Correlated Moves

Repligen Corp shares are higher today, bolstered by gains in Charles River Laboratories and positive sentiment in the life sciences sector.

4.08.2026 г., 19:56 ч. UTC

Repligen Corp shares are higher today, reflecting broader market strength amid a significant decline in crude oil prices. The stock is near its one-month range's upper end.

31.07.2026 г., 20:02 ч. UTC

Repligen Corp shares are lower today amid broader market pressures and rising US Treasury yields. The stock reached a session low earlier.

30.07.2026 г., 21:02 ч. UTC

Repligen Corp shares are higher in after-market trading, buoyed by positive investor sentiment amid a focus on corporate earnings and broader market trends.

29.07.2026 г., 16:12 ч. UTC

Repligen Corp shares are lower Wednesday, breaking a trend of higher daily closes. Broader market conditions reflect rising crude oil prices and inflation concerns.

28.07.2026 г., 23:21 ч. UTC

Repligen Corp shares are higher in after-market trading, reflecting strong momentum and trading near the upper end of its one-month range.

27.07.2026 г., 16:26 ч. UTC

News

Repligen Corporation shares are lower as the company approaches its Q2 earnings report, with analysts projecting 10.7% revenue growth. Current price is $131.96.

24.07.2026 г., 19:06 ч. UTC

News

Repligen Corp is under scrutiny as a stock to avoid, with concerns over its $763.3 million revenue and declining operating margins. Shares are trading lower today.

22.07.2026 г., 19:25 ч. UTC

News

Event

Social Media

Repligen Corp is acquiring BioLife Solutions for about $1.5 billion, offering $11.25 in cash and stock, with a projected $20 million in synergies.

21.07.2026 г., 22:56 ч. UTC

Repligen Corp shares are higher in after-market trading, despite a recent trend of lower closes. Broader market sentiment may be influenced by the Nikkei 225 surge.

20.07.2026 г., 18:06 ч. UTC

Repligen Corp shares are higher today, reflecting positive market sentiment despite earlier intraday fluctuations. No specific news was identified to explain the movement.

Сравнение с други в отрасъла

Ценова промяна

Repligen Corp Прогноза

Ценова цел

By TipRanks

8.74% нагоре

12-месечна прогноза

Среден 172.45 USD 8.74%

Висок 207 USD

Нисък 145 USD

Според 14 анализатори от Wall Street, предложили 12-месечна ценова цел за Repligen Corp през последните три месеца.

Консенсусна оценка

By TipRanks

Силна покупка

14 ratings

Купи

Задържане

Продай

Според 14 анализатори, дали борсови рейтинги на Repligen Corp през последните 3 месеца.

Настроение

By Acuity

46 / 340 Класиране в Здравеопазване

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Repligen Corp

Repligen Corporation develops and commercializes bioprocessing technologies and systems for use in biological drug manufacturing process in North America, Europe, the Asia Pacific, and internationally. It offers Protein A ligands that are the binding components of Protein A affinity chromatography resins; and cell culture growth factor products. The company's chromatography products include OPUS pre-packed chromatography columns, which are used in the purification of biologics; and OPUS smaller-scale columns that are used in the high throughput process development screening, viral clearance validation studies, and scale down validation of chromatography processes. It also offers ELISA test kits; and chromatography resins under the CaptivA brand. In addition, the company provides filtration products, such as XCell Alternating Tangential Flow systems that are filtration devices used in upstream perfusion and cell culture processing; TangenX flat sheet cassettes, which are used in downstream biologic drug concentration, buffer exchange, and formulation processes; KrosFlo tangential flow filtration and tangential flow depth filtration systems; Spectra/Por laboratory and process dialysis products, and ProConnex TFDF flow paths. Further, it provides process analytics products, such as slope spectroscopy systems under the SoloVPE, FlowVPE, and FlowVPX brands. The company sells its products to life sciences, biopharmaceutical, and diagnostics companies; laboratory researchers; and contract manufacturing organizations. Repligen Corporation has collaboration agreements with Navigo Proteins GmbH to develop multiple affinity ligands. The company was incorporated in 1981 and is headquartered in Waltham, Massachusetts.